1. ScholarBank@NUS

Alan Prem Kumar

rp02898

Collaboration Map View Statistics Email Alert RSS Feed

Profile

Full Name
Alan Prem Kumar
Variants
Kumar, A.P.
Kumar, A.
Prem Kumar, A.
Kumar, Alan Prem Rem
 
Main Affiliation
 
Faculty
 
Email
apkumar@nus.edu.sg
 
Other emails
 

Publications

Results 21-40 of 59 (Search time: 0.011 seconds).

Issue DateTitleAuthor(s)
21Aug-2020Role of microRNA/epithelial-to-mesenchymal transition axis in the metastasis of bladder cancerAshrafizadeh, M.; Hushmandi, K.; Hashemi, M.; Akbari, M.E.; Kubatka, P.; Raei, M.; Koklesova, L.; Shahinozzaman, M.; Mohammadinejad, R.; Najafi, M.; Sethi, G. ; Kumar, A.P. ; Zarrabi, A.
221-Jan-2021Putting the BRK on breast cancer: From molecular target to therapeuticsAng, Hui Li; Yuan, Yi ; Lai, Xianning ; Tan, Tuan Zea ; Wang, Lingzhi ; Huang, Benjamin BoJun; Pandey, Vijay; Huang, Ruby Yun-Ju; Lobie, Peter E ; Goh, Boon Cher ; Sethi, Gautam ; Yap, Celestial T ; Chan, Ching Wan ; Lee, Soo Chin ; Kumar, Alan Prem 
33-Aug-2020PTEN, a barrier for proliferation and metastasis of gastric cancer cells: From molecular pathways to targeting and regulationAshrafizadeh, M.; Najafi, M.; Ang, H.L.; Moghadam, E.R.; Mahabady, M.K.; Zabolian, A.; Jafaripour, L.; Bejandi, A.K.; Hushmandi, K.; Saleki, H.; Zarrabi, A.; Kumar, A.P. 
42018Pro-apoptotic and anti-cancer properties of diosgenin: A comprehensive and critical reviewSethi, G ; Shanmugam, M.K ; Warrier, S; Merarchi, M; Arfuso, F; Kumar, A.P ; Bishayee, A
51-Dec-2021Pre-Clinical and Clinical Applications of Small Interfering RNAs (siRNA) and Co-Delivery Systems for Pancreatic Cancer TherapyMirzaei, Sepideh; Gholami, Mohammad Hossein; Ang, Hui Li; Hashemi, Farid; Zarrabi, Ali; Zabolian, Amirhossein; Hushmandi, Kiavash; Delfi, Masoud; Khan, Haroon; Ashrafizadeh, Milad; Sethi, Gautam ; Kumar, Alan Prem 
6Jan-2013Potential role of signal transducer and activator of transcription (STAT)3 signaling pathway in inflammation, survival, proliferation and invasion of hepatocellular carcinomaSubramaniam, A.; Shanmugam, M.K. ; Perumal, E.; Li, F.; Nachiyappan, A.; Dai, X.; Swamy, S.N.; Ahn, K.S.; Kumar, A.P. ; Tan, B.K.H.; Hui, K.M.; Sethi, G.
72020Polychemotherapy with curcumin and doxorubicin via biological nanoplatforms: Enhancing antitumor activityAshrafizadeh, M.; Zarrabi, A.; Hashemi, F.; Zabolian, A.; Saleki, H.; Bagherian, M.; Azami, N.; Bejandi, A.K.; Hushmandi, K.; Ang, H.L.; Makvandi, P.; Khan, H.; Kumar, A.P. 
81-Dec-2023PI3K/AKT/mTOR signaling transduction pathway and targeted therapies in cancerGlaviano, A; Foo, ASC; Lam, HY ; Yap, KCH ; Jacot, W; Jones, RH; Eng, H ; Nair, MG; Makvandi, P; Geoerger, B; Kulke, MH; Baird, RD; Prabhu, JS; Carbone, D; Pecoraro, C; Teh, DBL; Sethi, G ; Cavalieri, V; Lin, KH; Javidi-Sharifi, NR; Toska, E; Davids, MS; Brown, JR; Diana, P; Stebbing, J; Fruman, DA; Kumar, AP 
924-Mar-2022PI3K/AKT Signaling Tips the Balance of Cytoskeletal Forces for Cancer ProgressionDeng, Shuo ; Leong, Hin Chong ; Datta, Arpita ; Gopal, Vennila; Kumar, Alan Prem ; Yap, Celestial T 
1026-Feb-2021Nrf2 signaling pathway in chemoprotection and doxorubicin resistance: potential application in drug discoveryMirzaei, Sepideh; Zarrabi, Ali; Hashemi, Farid; Zabolian, Amirhossein; Saleki, Hossein; Azami, Negar; Hamzehlou, Soodeh; Farahani, Mahdi Vasheghani; Hushmandi, Kiavash; Ashrafizadeh, Milad; Khan, Haroon; Kumar, Alan Prem 
111-Sep-2021New insight towards development of paclitaxel and docetaxel resistance in cancer cells: EMT as a novel molecular mechanism and therapeutic possibilitiesAshrafizadeh, Milad; Mirzaei, Sepideh; Hashemi, Farid; Zarrabi, Ali; Zabolian, Amirhossein; Saleki, Hossein; Sharifzadeh, Seyed Omid; Soleymani, Leyla; Daneshi, Salman; Hushmandi, Kiavash; Khan, Haroon; Kumar, Alan Prem ; Aref, Amir Reza; Samarghandian, Saeed
1217-Jun-2022(Nano)platforms in bladder cancer therapy: Challenges and opportunitiesAshrafizadeh, Milad; Zarrabi, Ali; Karimi-Maleh, Hassan; Taheriazam, Afshin; Mirzaei, Sepideh; Hashemi, Mehrdad; Hushmandi, Kiavash; Makvandi, Pooyan; Nazarzadeh Zare, Ehsan; Sharifi, Esmaeel; Goel, Arul; Wang, Lingzhi ; Ren, Jun; Nuri Ertas, Yavuz; Kumar, Alan Prem ; Wang, Yuzhuo; Rabiee, Navid; Sethi, Gautam ; Ma, Zhaowu
13Feb-2012Multifaceted link between cancer and inflammationSethi, G.; Shanmugam, M.K. ; Ramachandran, L.; Kumar, A.P. ; Tergaonkar, V.
141-Jan-2018Molecular targets and anti-cancer potential of escinCheong, Dorothy HJ ; Arfuso, Frank; Sethi, Gautam ; Wang, Lingzhi ; Hui, Kam Man ; Kumar, Alan Prem ; Thai, Tran 
151-Dec-2022Molecular Landscape of LncRNAs in Prostate Cancer: A focus on pathways and therapeutic targets for interventionMirzaei, S; Paskeh, MDA; Okina, E ; Gholami, MH; Hushmandi, K; Hashemi, M; Kalu, A; Zarrabi, A; Nabavi, N; Rabiee, N; Sharifi, E; Karimi-Maleh, H; Ashrafizadeh, M; Kumar, AP ; Wang, Y
1621-Sep-2021Mast cells: Therapeutic targets for COVID-19 and beyondLam, Hiu Yan ; Tergaonkar, Vinay ; Kumar, Alan Prem ; Ahn, Kwang Seok
172018Magnolol: A neolignan from the Magnolia family for the prevention and treatment of cancerRanaware A.M.; Banik K.; Deshpande V.; Padmavathi G.; Roy N.K.; Sethi G. ; Fan L.; Kumar A.P. ; Kunnumakkara A.B.
18May-2019Long non-coding RNAs are emerging targets of phytochemicals for cancer and other chronic diseasesMishra, Shruti; Verma, Sumit S; Rai, Vipin; Awasthee, Nikee; Chava, Srinivas; Hui, Kam Man; Kumar, Alan Prem ; Challagundla, Kishore B; Sethi, Gautam ; Gupta, Subash C
19Dec-2017'Lnc'-ing Wnt in female reproductive cancers: therapeutic potential of long non-coding RNAs in Wnt signallingOng, Mei S; Cai, Wanpei ; Yuan, Yi; Leong, Hin C ; Tan, Tuan Z ; Mohammad, Asad; You, Ming L; Arfuso, Frank; Goh, Boon C ; Warrier, Sudha; Sethi, Gautam ; Tolwinski, Nicholas S; Lobie, Peter E ; Yap, Celestial T ; Hooi, Shing C ; Huang, Ruby Y ; Kumar, Alan P 
2015-Nov-2012Key cell signaling pathways modulated by zerumbone: Role in the prevention and treatment of cancerPrasannan, R.; Kalesh, K.A.; Shanmugam, M.K. ; Nachiyappan, A.; Ramachandran, L.; Nguyen, A.H.; Kumar, A.P. ; Lakshmanan, M.; Ahn, K.S.; Sethi, G.